<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04490330</url>
  </required_header>
  <id_info>
    <org_study_id>PI2019_843_0106</org_study_id>
    <nct_id>NCT04490330</nct_id>
  </id_info>
  <brief_title>Screening for Alcohol-related Cognitive Impairments in Cirrhotic Patients</brief_title>
  <acronym>CirCo</acronym>
  <official_title>Screening for Alcohol-related Cognitive Impairments in Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      80% of patients with alcohol use disorders (AUD) present cognitive impairments, such as&#xD;
      memory and executive functions. These disorders may have repercussions in addiction treatment&#xD;
      by altering the patient's adherence to care. The level of impairment is dependent on the&#xD;
      onset of addiction, and also the duration of abstinence.&#xD;
&#xD;
      A complete neuropsychological evaluation is necessary to highlight cognitive impairments. In&#xD;
      practice, the evaluation of these disorders by practitioners, is done with the help of tools&#xD;
      of screening like the MoCa (Montreal cognitive assesment) and the BEARNI (Brief evaluation of&#xD;
      alcohol related neuropsychological impairment).&#xD;
&#xD;
      However, none of these tools have been evaluated in patients with alcoholic cirrhosis.&#xD;
      Indeed, some studies have suggested that liver disorders including cirrhosis may be a factor&#xD;
      aggravating cognitive disorders.&#xD;
&#xD;
      The purpose of this study is to evaluate the ability of the BEARNI tool to detect&#xD;
      alcohol-related cognitive problems in patients with alcohol-related cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Actual">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of alcoholic cirrhosis patients with presence of alcohol-related cognitive disorders</measure>
    <time_frame>day 1</time_frame>
    <description>the number of alcoholic cirrhosis patients with presence of alcohol-related cognitive disorders will be measured by using the BEARNI screening tool. BEARNI screening tool is Brief evaluation of alcohol related neuropsychological impairment.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Dependence</condition>
  <condition>Cognitive Impairments</condition>
  <condition>Cirrhosis</condition>
  <condition>Liver Diseases</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire</intervention_name>
    <description>AUDIT questionnaire (alcohol use disorders identification test)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with alcoholic cirrhosis will be evaluated with BEARNI tool in order to detect&#xD;
        alcohol-related cognitive problems.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with cirrhosis&#xD;
&#xD;
          -  patients with cirrhosis diagnosed by clinical examination&#xD;
&#xD;
          -  patients with cirrhosis diagnosed by biological and / or morphological and / or&#xD;
             noninvasive tests and / or liver biopsy&#xD;
&#xD;
          -  CHILD A, B or C&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hepatitis encephalopathy less than 6 months old&#xD;
&#xD;
          -  complicated cirrhosis with hepatocellular carcinoma&#xD;
&#xD;
          -  Acute alcoholic hepatitis&#xD;
&#xD;
          -  viral cirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bernard ANGERVILLE, MD</last_name>
    <phone>(33)322068297</phone>
    <email>angerville.bernard@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard ANGERVILLE, MD</last_name>
      <phone>(33)322068297</phone>
      <email>angerville.bernard@chu-amiens.fr</email>
    </contact>
    <contact_backup>
      <last_name>Eric NGUYEN -KHAC, Pr</last_name>
      <phone>(33)322088851</phone>
      <email>nguyenkhac.eric@chu-amiens.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Dependence</keyword>
  <keyword>Cognitive Impairments</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Liver Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

